News & Updates

Analogue insulin demonstrates superiority over human insulin in terms of survival among patients with kidney failure and type 2 diabetes (T2D) who are receiving peritoneal dialysis, according to a study presented at ERA 2025.

The phase II CONFIDENCE* trial shows the benefit of dual therapy with the selective ns-MRA** finerenone and the SGLT2i** empagliflozin vs either agent alone in individuals with chronic kidney disease (CKD) and type 2 diabetes (T2D).

In patients with chronic kidney disease and type 2 diabetes who have not been previously treated with any mineralocorticoid receptor antagonist (MRA), the use of finerenone results in marked reductions in albuminuria, reports a study presented at ERA 2025.

Adverse childhood experiences (ACEs), such as abuse, neglect, and household dysfunction, appear to contribute to the development of obesity during adulthood, suggests an Iraq study presented at ESPGHAN 2025.

In paediatric patients with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), treatment with GLP-1 receptor agonists (RAs) results in a decrease in depression and substance use, as shown in a study presented at ESPGHAN 2025.

Lifestyle modification induced remission of metabolic dysfunction–associated steatotic liver disease (MASLD) in a higher proportion of people living with HIV (PLHIV) than standard care, according to the first randomized controlled trial (RCT) of its kind conducted by researchers from the Chinese University of Hong Kong (CUHK).